心理健康、疲劳与功能状态与类风湿关节炎患者TNF抑制剂减量后疾病复发风险增加相关:OPTTIRA试验数据的探索性分析
本研究为OPTTIRA随机对照试验的事后分析,纳入97例持续低疾病活动度的类风湿关节炎患者,随机按33%或66%减量抗TNF治疗。41例患者出现复发。基线DAS28较高与复发相关(校正HR 1.96),SF-36心理健康评分是复发的独立预测因素(每10单位校正HR 0.74)。作者认为抗TNF减量决策中应考虑心理健康与功能状态。
要点
- 基线DAS28较高与减量后复发独立相关(校正HR 1.96,95%CI 1.18-3.24,p=0.01)。
- SF-36心理健康评分是复发的独立预测因素(每10单位校正HR 0.74,95%CI 0.60-0.93,p=0.01)。
- 疲劳与功能状态在未校正模型中预测复发,校正混杂因素后效应消失。
核心结论
- 基线DAS28与心理健康状态独立地与接受抗TNF减量治疗患者的复发相关。
- 疲劳与功能状态也与复发相关,但校正混杂因素后效应消失。
- 作者认为抗TNF减量决策中应考虑心理健康与功能状态,以优化减量成功的可能性。
研究设计与样本
- 本研究为OPTTIRA试验的事后分析;OPTTIRA为多中心、随机、开放标签研究,评估持续低疾病活动度类风湿关节炎患者的抗TNF减量。
- 97例患者被随机分配至抗TNF剂量减量33%或66%两组。
- 基线时收集患者报告结局:健康评估问卷(HAQ)、EuroQol五维量表、慢性病治疗功能评估疲劳量表(FACIT-F)、36项简表调查(SF-36)。
- 主要结局为复发,定义为28关节计数疾病活动度评分(DAS28)增加≥0.6且肿胀关节数≥1。
- 采用离散时间生存模型识别预测复发的患者报告结局。
主要发现
- 97例患者中41例出现复发。
- 基线DAS28较高与复发相关(校正HR 1.96,95%CI 1.18-3.24,p=0.01)。
- 残疾(SF-36躯体成分评分)、疲劳(FACIT-F)与心理健康(SF-36心理健康子量表(MH))在未校正模型中预测复发。
- 多变量分析中仅SF-36 MH仍为复发的统计学显著预测因素(每10单位校正HR 0.74,95%CI 0.60-0.93,p=0.01)。
关键数值与推荐
- 复发定义:DAS28增加≥0.6且肿胀关节数≥1。
- 基线DAS28与复发的校正HR为1.96(95%CI 1.18-3.24),p=0.01。
- SF-36心理健康子量表每10单位的校正HR为0.74(95%CI 0.60-0.93),p=0.01。
临床怎么用
- 作者认为,基于这些发现,抗TNF减量决策中应考虑心理健康与功能状态,以优化减量成功的可能性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tapering of anti-tumour necrosis factor (TNF) therapy appears feasible, safe and effective in selected patients with rheumatoid arthritis (RA). Depression is highly prevalent in RA and may impact on flare incidence through various mechanisms. This study aims to investigate if psychological states predict flare in patients' dose tapering their anti-TNF therapy. METHODS: This study is a post-hoc analysis of the Optimizing TNF Tapering in RA trial, a multicentre, randomised, open-label study investigating anti-TNF tapering in RA patients with sustained low disease activity. Patient-reported outcomes (Health Assessment Questionnaire, EuroQol 5-dimension scale, Functional Assessment of Chronic Illness Therapy fatigue scale (FACIT-F), 36-Item Short Form Survey (SF-36)) were collected at baseline. The primary outcome was flare, defined as an increase in 28-joint count Disease Activity Score (DAS28) ≥0.6 and ≥1 swollen joint. Discrete-time survival models were used to identify patient-reported outcomes that predict flare. RESULTS: Ninety-seven patients were randomised to taper their anti-TNF dose by either 33% or 66%. Forty-one patients flared. Higher baseline DAS28 score was associated with flare (adjusted HR 1.96 (95% CI 1.18 to 3.24), p=0.01). Disability (SF-36 physical component score), fatigue (FACIT-F) and mental health (SF-36 mental health subscale (MH)) predicted flare in unadjusted models. In multivariate analyses, only SF-36 MH remained a statistically significant predictor of flare (adjusted HR per 10 units 0.74 (95% CI 0.60 to 0.93), p=0.01). CONCLUSIONS: Baseline DAS28 and mental health status are independently associated with flare in patients who taper their anti-TNF therapy. Fatigue and function also associate with flare but the effect disappears when adjusting for confounders. Given these findings, mental health and functional status should be considered in anti-TNF tapering decisions in order to optimise the likelihood of success. TRIAL REGISTRATION NUMBERS: EudraCT Number: 2010-020738-24; ISRCTN: 28955701; Post-results.
引用
- Bechman K, Sin FE, Ibrahim F, et al. Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial. RMD Open. 2018. PMID: 29862047. doi:10.1136/rmdopen-2018-000676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。